Visen Pharmaceuticals Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 102

Employees

  • Stock Symbol
  • 02561

Stock Symbol

  • Share Price
  • $1.54
  • (As of Tuesday Closing)

Visen Pharmaceuticals General Information

Description

VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Room 2501, 1788 International Building
  • 1788 Nanjing West Road, Jing'an District
  • Shanghai
  • China
+86 021
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Room 2501, 1788 International Building
  • 1788 Nanjing West Road, Jing'an District
  • Shanghai
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visen Pharmaceuticals Stock Performance

As of 17-Nov-2026, Visen Pharmaceuticals’s stock price is $1.54. Its current market cap is $168M with 109M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.54 $1.60 $1.39 - $5.55 $168M 109M 9.9K -$0.32

Visen Pharmaceuticals Financials Summary

As of 30-Jun-2026, Visen Pharmaceuticals has a trailing 12-month revenue of $4.96M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 225,233 329,510
Revenue 4,960 23 0 0
EBITDA (34,902) (36,285) (25,697) (35,817)
Net Income (34,228) (35,240) (25,398) (35,276)
Total Assets 130,574 139,680 40,249 62,607
Total Debt 26,008 25,296 323 515
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Visen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Visen Pharmaceuticals‘s full profile, request access.

Request a free trial

Visen Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments
Pharmaceuticals
Shanghai, China
102 As of 2026

Changchun, China
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visen Pharmaceuticals Competitors (1)

One of Visen Pharmaceuticals’s competitors is GeneScience Pharmaceuticals Co., a Corporate Backed or Acquired company based in Changchun, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GeneScience Pharmaceuticals Co. Corporate Backed or Acquired Changchun, China
You’re viewing 1 of 1 competitors. Get the full list »

Visen Pharmaceuticals Patents

Visen Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026021075-A1 Freeze-drying method for pharmaceuticals, cosmetics or medical beauty products, freeze-dried formulation and injection Pending 26-Jul-2024
WO-2026021076-A1 Lyophilization method for lonapegsomatropin, lyophilized formulation of lonapegsomatropin, and injection Pending 26-Jul-2024
WO-2026021074-A1 Vial cap assembly Pending 26-Jul-2024 B65D41/28

Visen Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visen Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Visen Pharmaceuticals’s complete esg history, request access »

Visen Pharmaceuticals FAQs

  • When was Visen Pharmaceuticals founded?

    Visen Pharmaceuticals was founded in 2018.

  • Where is Visen Pharmaceuticals headquartered?

    Visen Pharmaceuticals is headquartered in Shanghai, China.

  • What is the size of Visen Pharmaceuticals?

    Visen Pharmaceuticals has 102 total employees.

  • What industry is Visen Pharmaceuticals in?

    Visen Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Visen Pharmaceuticals a private or public company?

    Visen Pharmaceuticals is a Public company.

  • What is Visen Pharmaceuticals’s stock symbol?

    The ticker symbol for Visen Pharmaceuticals is 02561.

  • What is the current stock price of Visen Pharmaceuticals?

    As of 17-Nov-2026 the stock price of Visen Pharmaceuticals is $1.54.

  • What is the current market cap of Visen Pharmaceuticals?

    The current market capitalization of Visen Pharmaceuticals is $168M.

  • What is Visen Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Visen Pharmaceuticals is $4.96M.

  • Who are Visen Pharmaceuticals’s competitors?

    GeneScience Pharmaceuticals Co. is a competitor of Visen Pharmaceuticals.

  • What is Visen Pharmaceuticals’s annual earnings per share (EPS)?

    Visen Pharmaceuticals’s EPS for 12 months was -$0.32.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process